C
CereVasc
Developing solutions for the treatment of patients with communicating hydrocephalus
About CereVasc
CereVasc, Inc. is a medical device company focused on developing innovative endovascular solutions for the treatment of communicating hydrocephalus, a condition characterized by an abnormal accumulation of cerebrospinal fluid in the brain. The company's flagship product, the eShunt System, is currently under development and aims to offer a less invasive alternative to traditional surgical methods. This system has the potential to deliver therapy across the blood-brain barrier, reducing the complications and uncertainties associated with current treatments like intrathecal injections or ommaya reservoir implantation. CereVasc operates primarily in the medical device market, targeting healthcare providers and institutions that treat neurological conditions. The company generates revenue through the development and eventual commercialization of its patented technologies. By aggressively pursuing patent protection both in the United States and internationally, CereVasc aims to secure a competitive edge in the market. The business model involves continuous innovation and development of its core technologies, followed by strategic partnerships and licensing agreements to bring these solutions to market. Keywords: endovascular, hydrocephalus, eShunt System, blood-brain barrier, intrathecal injection, ommaya reservoir, patent protection, medical device, neurological treatment, healthcare.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Boston, United States
- Employees
- 36
- Open positions
- 1
- Dealroom signal
- 84.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Clinical, Neurology, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning CereVasc.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2026 | $85M | $340M | Bain Capital Life Sciences · Perceptive Xontogeny Venture Fund · Medtronic · Johnson & Johnson Innovation | ↗ |
| SERIES BOther financing | May 2024 | $70M | $280M | Bain Capital Life Sciences · Perceptive Xontogeny Venture Fund | ↗ |
Growth signals
Latest recorded traffic for CereVasc is 3.6K monthly website visits, up 0% over the last three months. CereVasc's team grew 2.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Yonghua Capital
ATON Partners
Perceptive Advisors
Xontogeny
Bain Capital Life Sciences- PFPerceptive Xontogeny Venture Fund
Series B and later3 investors entered at this stage
Piper Sandler
Medtronic
Johnson & Johnson Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CereVasc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CereVasc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






